While recent clinical trials of magrolimab with azacitidine +/- venetoclax in AML were not successful, our work suggests that there may be important mechanistic differences between the drugs that target CD47, and that it is still worthwhile to pursue further study of targeting this pathway therapeutically, especially for cases that are resistant to BCL-2 inhibition. This evidence concerns the gene CD47 and acute myeloid leukemia.